Pardoprunox

DRUG5 trials

Sponsors

Solvay Pharmaceuticals, Abbott Products

Conditions

Advanced Stage Parkinson's DiseaseEarly Stage Parkinson's Disease

Phase 2

A Pilot Study to Assess Efficacy and Safety of Pardoprunox as Adjunct Therapy to L-dopa in the Treatment of Patients With Parkinson's Disease Experiencing Motor Fluctuations and Dyskinesia.

TerminatedNCT00903838

Abbott ProductsAdvanced Stage Parkinson's Disease

Start: 2009-09-30End: 2011-05-31Updated: 2011-08-26

Phase 3

SLV308 for Treatment of Patients With Early Parkinson's Disease

CompletedNCT00269516

Solvay PharmaceuticalsEarly Stage Parkinson's Disease

Start: 2006-06-30End: 2007-12-31Updated: 2008-08-29

SLV308 for Treatment of Patients With Early Parkinson's Disease

CompletedNCT00269516

Solvay PharmaceuticalsEarly Stage Parkinson's Disease

Start: 2006-06-30End: 2007-12-31Updated: 2008-08-29

An Open Label SLV308 Safety Extension to Study S308.3.001 in Early PD Patients

CompletedNCT00332917

Solvay PharmaceuticalsEarly Stage Parkinson's Disease

Start: 2007-02-28End: 2008-07-31Updated: 2009-01-26

An Open Label SLV308 Safety Extension to Study S308.3.003 in Early PD Patients

CompletedNCT00335374

Solvay PharmaceuticalsEarly Stage Parkinson's Disease

Start: 2007-08-31End: 2008-11-30Updated: 2009-02-06

An Open Label SLV308 Safety Extension to Study S308.3.002 in Patients With Parkinson's Disease Experiencing Motor Fluctuations.

CompletedNCT00407095

Solvay PharmaceuticalsAdvanced Stage Parkinson's Disease

Start: 2007-08-31End: 2009-05-31Target: 140Updated: 2010-09-13